
News|Articles|December 3, 2025
Unlocking Speed and Scalability in Biologics: GPEx® Lightning Executive Overview
Author(s)Catalent
Discover how Catalent’s GPEx® Lightning platform revolutionizes cell line development for complex biologics. This executive summary highlights how the platform enables rapid, high-titer expression of multispecific antibodies and other challenging proteins—accelerating timelines, improving production efficiency, and supporting commercial-scale manufacturing. Learn how tunable expression and digital control empower your team to overcome development bottlenecks and drive innovation in next-generation biologics.
Trending on Pharmaceutical Technology
1
What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation
2
CAR T-Cell Trial Pause Signals New Manufacturing Risk Review
3
AAPS PharmSci 360: CMC Strategies, Part 1
4
AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1
5
